Highlights newsletter 3
This newsletter presents you the following key sessions:
1. Video-interview M. André about the five-year survival data of brentuximab vedotin in patients with relapsed
or refractory systemic anaplastic large cell lymphoma
2. Subcutaneous or intravenous rituximab? The SABRINA study
3. Potential improvements in quality of life for hemophilia patients using adeno-associated virus mediated
gene transfer
4. Cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia patients with deep molecular
response: results of the EURO-SKI trial
5. More relapses with reduced intensity delayed intensification in standard-risk children with acute
lymphoblastic leukemia